

Michael Davidson, MD

E-mail: mdavidson6@gmail.com

Tel +972524446520

Licensed to practice medicine in Israel and New York State (not-active)

Board-certified in Psychiatry in Israel and US

Education and Employment

1970-1976 MD Degree State University of Milan Medical School, Italy
1976-1980 Resident in Cardiology and Medicine, Tel Aviv Medical Centre
1981-1985 Resident in Psychiatry Mount Sinai School of Medicine NY
1985-1995 Unit Head and Division Director Mount Sinai N.Y
1991-1995 Associate Director for R&D, Pilgrim Psychiatric Hospital, NY
1995-1999 Psychiatric Services and Memory Clinic Sheba Medical Centre Tel-Aviv
2000-2001 Associate Director Abarbanel Psychiatric Hospital Tel-Aviv
2001-2012 Chief Psychiatrist Dep. of Psychiatry Sheba Medical Centre Tel-Aviv
2012-2016 Chief Psychiatrist Dep. of Psychiatry B Sheba Medical Centre Tel-Aviv
2000-current President The Israeli Medical Centre for Alzheimer
2003-2016 Co-Founder Tangent Data CRO Bucharest Romania
2009-2014 Chief Editor European Neuropsychopharmacology
2014-current Associate Editor European Neuropsychopharmacology
2012-2013 Department of Psychiatry Mount Sinai School of Medicine New York
2016-current Chief Medical Officer Minerva Neurosciences Inc. Mass. USA

Academic Appointments

1993-1995 Professor of Psychiatry Mount Sinai School of Medicine N.Y.
1996-current Professor of Psychiatry Tel Aviv University (emeritus)
1996-current Professor of Psychiatry Mount Sinai School of Medicine NY (secondary)
2006- 2010 Chairman Department Psychiatry Tel Aviv University
2019-current Chairman Department Psychiatry Nicosia University

Teaching Experience Brief summary and highlights of courses and symposiums:
Students' Tutor Mount Sinai Medical School 1984-87
Research Methodology Bronx Veteran Administration 1986-88
Medical comorbidities Mount Sinai Medical School 1989-90
Residency selection and training committee 1990-93
Schizophrenia for Medical Residents Tel Aviv University 1995-2013
Psychopharmacology School of Social Work Bar Ilan Univ. 1997-2000
Teaching Committee International Psychogeriatric Association 1996-98
Research Methodology and Psychopharmacology for European College of Neuropsychopharmacology courses 1997-2016

Awards, Membership in Professional Societies and Advisory Boards

ECNP Psychopharmacology Award 1997

CINP Neuroscience Award 2006

ACNP Fellow

Board Member International Psychogeriatric Association Chair Publication Committee(past)
Reviewer or board member: Archives of General Psychiatry; American Journal of Psychiatry;
Biological Psychiatry; Schizophrenia Bulletin; Schizophrenia Research; Psychiatry, Dialogues in
Neurosciences, Alzheimer's disease and Related Disorders Journal

Stocks Tangent, Minerva Neurosciences

Patents WO 2008/058181

Advisory boards

Pfizer, JNJ, Teva, Roche, Novartis, Lilly, Forest, BioLineRx, Lundbeck, PRC, Sanofi-Aventis, Otsuka, Takeda, Orion, Servier.

Grants

- ♦ Stanley Foundation Nicotine allosteric compound in Bipolar disorder 540 000 \$ 2015-2017
- ♦ EULAST 2014-2017 to compare depot and oral Antipsychotics CO-PI 2014-2020
- ♦ European Community F7 grant to study schizophrenia IL Principal Investigator 2010-2014
- ♦ NIH awarded grant to study the link between diabetes and Alzheimer's Disease 2009-2014 PI for Israel \$ 1 000 000
- ♦ European Consortium to compare among atypical antipsychotics National Coordinator 2003-2007
- ♦ Cognitive Impairment as Endo-phenotype for schizophrenia PI NIMH 2004-2008; \$ 1.800.000
- ♦ Early detection and intervention in schizophrenia CO-PI Israeli-German Collaboration 2001-2005 \$400.000
- ♦ Effect of D-serine on negative symptoms of schizophrenia Co-Investigator 1.500 000 \$ Stanley foundation 2004-2007
- ♦ Epidemiology and risk factors of schizophrenia Stanley foundation CO-PI 400 000 2004-200
- ♦ Perinatal Risk Factors for Schizophrenia NIMH Co-Investigator IL supplement \$200,000 2000-2005
- ♦ Cost of care of Alzheimer's Disease 1997-2000 Gertner Institute for Health policies \$100.000
- ♦ Cardiovascular Risk Factors for Alzheimer's Disease PI Israeli Academy of Science 2000-2001 \$50,000
- ♦ Aricept + Risperidal in cognitively impaired schizophrenic patients \$ 45 0000 1998-2000
- ♦ Exelon + Risperidal in behaviorally disturbed demented patients \$ 90 0000 1999-2000
- ♦ Three Fixed Dosage Regimens of L-693, 487 in Alzheimer's Disease, PI, 1991-1992, \$80,000
- ♦ Efficacy trial of AF 102 in Alzheimer's Disease patients Co-PI. Teva 1995-1996 \$ 45,000
- ♦ Alzheimer's Disease Research Center: The Efficacy of THA in Alzheimer's Disease and Senile Dementia of the Alzheimer's Type: A Multicenter Study, Co-Investigator, NIH 1984-1989, \$288,840.
- ♦ Effects of Scopolamine on CBF CO-Investigator. Israeli Foundation for Biological Psychiatry \$10,000
- ♦ Cholinergic Treatment of Memory Deficits, Co-Investigator, NIH 1980-1995, \$3,339,591.
- ♦ Alzheimer's Disease Research Center, Co-investigator, National Institute of Aging, 1989-1994, \$1,900,000.
- ♦ Neurochemistry of Dementia in Elderly Schizophrenics, PI, Veterans Administration, 1992-1996, \$612,807.

- ♦ Neuropathology of Dementia in Elderly Schizophrenics PI, NIMH, 1990-1995, \$1,278,605.
- ♦ Schizophrenia Biologic Research Center, Co-Director, Veterans Administration, 1986-1995, \$1,062,108
- ♦ Computerized Visual Motor Tasks To Measure Cognition in Schizophrenia Part I Co-PI \$100,000 1999-2002
- ♦ Design assessment and referral algorithm for adolescents rejected by the Draft Board because of mental illness Makaria Foundation CO-PI \$ 100,000 2002-2004
- ♦ Rate of smokers among healthy adolescents destined to develop schizophrenia (an historical prospective study) NARSAD Distinguished Investigator \$100,000; 2002-2004
- ♦ Stanley Foundation Center Grant on Schizophrenia 2002-2006 \$300,000
- ♦ Economic Determinants and incentives for de-institutionalization in Israel 1999-2001 \$70,000
- ♦ Predicting Schizophrenia in apparently Healthy individuals Stanley Foundations 2000-2002 \$150,000
- ♦ Cellular and Molecular Markers in Schizophrenia, Co-Investigator, NIH 1990-1995, \$4,513,399.
- ♦ Immunohistochemistry of neuropeptide in schizophrenics PI, Stanley Foundation 1996-1997, \$47,000.
- ♦ Medication choices in Schizophrenia based on the gambling system Co-PI, NAMI 1995-1997, \$32,000
- ♦ Risperidone in the Treatment of Negative Symptoms in Schizophrenia, PI Janssen 1992-1994, \$120,000
- ♦ Toward a Rational Use of Plasma HVA in Schizophrenia, PI, NIH, 1989-1993, \$632,622
- ♦ Changes in Plasma homovanilic Acid Concentrations in Schizophrenic Patients During Change of State From Remission to Exacerbation, PI, Merit Review Veterans Administration, 1989-1992, \$249,999.
- ♦ Serotonin in Treatment Refractory Schizophrenia, Co-Investigator, NIH, 1990-1991, \$89,963
- ♦ Evaluation of Tolerance and Steady-State Pharmacokinetics of HP873 in Schizophrenia: 1993, \$117,000
- ♦ Open-Label Dose-Finding Safety and Efficacy of BMY 14802-1 in Schizophrenia: PI 1990-1991, \$70,000.
- ♦ Safety and Efficacy Evaluation of ICI 204,636 in Acute Psychotics, 1989-1991, \$75,000
- ♦ Phase III trial SKB 2004 cholinergic agonist in Alzheimer's Disease Patients, PI, 1996-1997, \$ 50,000
- ♦ Double-blind trial of Risperidone vs Haloperidol in early psychotic patients, National Coordinator 1997-2003,
- ♦ Risperidone vs Olanzapine in Elderly schizophrenic patients National Coordinator 1997-2000
- ♦ Ilperidone in chronic schizophrenic patients 1998-2000
- ♦ Ilperidone in demented patients 1999-2000
- ♦ Aricept in AD 1999-2000
- ♦ Propentophyline in AD National Coordinator 1999-2000
- ♦ Exelon in AD 2000-2001

- ♦ Galantamine in MCI 2002-2004
- ♦ Galantamine in AD and VD patients National Coordinator 2000-2002
- ♦ AF201 in AD Teva 1997-1998

LIST OF PUBLICATIONS

1. **Davidson M** . Gabos C. Do DSM classifications help or hinder drug development Dialogues in Clinical Neurosciences September 2020
2. Strauss, G.P., Zamani-Esfahlani, F., Sayama, H., Kirkpatrick, B., Opler, M., Saoud, J.B., **Davidson, M.**, Luthringer, R. (Schiz Bull 2020). Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: Evidence from the roluperidone clinical trial. Schizophrenia Bulletin. 2020
3. Levi L, Bar Haim M,.... **Davidson M** Kahn R, Weiser M, Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort. European Neuropsychopharmacology Feb 2020
4. Marder S, **Davidson M**, Luthringer R, Daniel D. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia: consensus statements Schiz Bull Open; February, 2020
5. Daniel D, Kott A, Saoud J, Luthringer, Rud V, Skyrpnikov A, Stan R, Palazov V, Wang X, **Davidson M**. Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo [Innovations in Clinical Neuroscience 2020](#)
6. Weiser M Levy .L **Davidson M** Effects of adjunctive oestradiol on symptoms of schizophrenia Psychiatry. 2019;76(10):1009-1017.
7. **Davidson M** Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia Word Psychiatry 2019 Jun;18(2):171-172
8. Harvey PD, Saoud J, Luthringer R, Moroz M, Blazhevych Y, Stefanescu C , **Davidson M** Effects of Roluperidone (MIN-101) on Two Dimensions of the Negative Symptoms Factor Score: Reduced Emotional Experience and Reduced Emotional Expression. Schizophr Res. Jan vol 215 pp 352-356; 2020.
9. Reichenberg A. Velthorst E **Davidson M**. Cognitive impairment and psychosis in schizophrenia, linked or independent conditions Word Psychiatry 2019,Jun;18(2)
10. **Davidson M**, Thibaut F. Modifying Therapies in Dementia, Editorial Dialogues in Clinical Neurosciences 2019
11. Kodesh A, Sandin S, Reichenberg A, Rotstein A, Pedersen N, Ericsson M, Karlsson I, **Davidson M**, Levine SZ. (2019) Exposure to Antidepressant Medication and the Risk of Incident Dementia. *The American Journal of Geriatric Psychiatry*. Published online. IF (2018)=3.488; R=19/53 (Q2) in Gerontology (SSCI), R=47/146 (Q2)) in Psychiatry (SSCI).
12. Rabinowitz J**Davidson M** Luthringer R Personal and Social Adjustment Effects of Roluperidone in Patients with Schizophrenia and Negative Symptoms: Results from a Randomized Placebo-Controlled Trial Schizophrenia Research 2019

13. Weiser M. ... **Davidson M.**, Sven Sandin PhD Understanding the Association between Advanced Paternal Age and Schizophrenia and Bipolar disorder *Psychological Medicine* 2019 Mar 4:1-7.
14. Levine S **Davidson M** Kodis "Exposure to Antidepressant Medication and the Risk of Incident Dementia" *Am J Geriatric Psychiatry* 2019
Weiser M, Levi L, Burshtein S, Chiriță R, Cirjaliu D, Gonen I, Yolken R, **Davidson M**, Zamora D, Davis JM. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. *Schizophr Res.* 2019 Apr;206:325-332.
15. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. *Nat Genet.* 2019 May 13. Part Of Group Authorship
16. Keefe RSE, Harvey PD, Khan A, Saoud JB, Staner C, **Davidson M**, Luthringer R. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. *J Clin Psychiatry.* 2018 May/Jun
17. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry.* 2018 Oct;5(10):797-807 Part Of Group Authorship
18. Anttila V,... **Davidson M**,... Murray R..... Analysis of shared heritability in common disorders of the brain. *Science.* 2018 Jun 22;360(6395).
19. **Davidson M.** The debate regarding maintenance treatment with antipsychotics drugs in schizophrenia. *Dialogues in Clinical Neurosciences* 215-222; 2018
20. Large M, Myles N, Myles H, Corderoy A, Weiser M, **Davidson M**, Ryan CJ. Suicide risk assessment among psychiatric inpatients: a systematic review and meta-analysis of high-risk categories. *Psychol Med.* 2018 May;48(7):1119-1127.
21. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Age at first birth in women is genetically associated with increased risk of schizophrenia. *Sci Rep.* 2018 Jul 5;8(1) Part Of Group Authorship
22. Popovic D, Goldberg S, Fenchel D, Frenkel O, Reichenberg A, Yoffe R, **Davidson M**, Weiser M Risk of hospitalization for psychiatric disorders among siblings and parents of probands with psychotic or affective disorders: A population-based study. *Eur Neuropsychopharmacol.* 2018 Mar;28(3):436-443
23. **Davidson M.**, Saoud J., Staner C., Noel N., Luthringer E., Werner S., Reilly J., Schaffhauser JY., Rabinowitz J., Weiser M., Luthringer R. Efficacy and Safety of MIN-101: A New Drug for the Treatment Of Negative Symptoms in Schizophrenia A 12-Week Randomized, Double Blind, Placebo-Controlled Trial *American Journal of Psychiatry* Dec 1;174(12):1195-1202; 2017
24. Large M, **Davidson M**Weiser M Suicide Risk Assessment Among Psychiatric Inpatients: a Systematic Review and Meta-analysis of High-risk Categories *Psychological Medicine* pp 1-12; 2017
25. Kirkpatrick B, Saoud JB, Strauss GP, Ahmed AO, Tatsumi K, Opler M, Luthringer R, **Davidson M**. The brief negative symptom scale (BNSS): Sensitivity to treatment effects. *Schizophrenia Research* 2017
26. **Davidson M.** Vaccination as a cause of autism-myths and controversies. *Dialogues Clin Neurosci.* 2017 Dec;19(4):403-407.

27. Rabinowitz J, Schooler N **Davidson M**, Opler MZhao J Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS) Schiz Research Schizophrenia Research 190 (2017) 74–76
28. Livni A, Reichenberg A,.....**Davidson M**, Weiser M . A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis Am Journal of Psychiatry 2017
29. Large M, **Davidson M**, Weiser M Inpatient suicide: selection of people at risk, failure of protection and the possibility of causation British Journal of Psychiatry 2017
30. Howes O **Davidson M** Kane J Treatment Resistant Schizophrenia Consensus and Guidelines American Journal of Psychiatry 216-229; 2017
31. Rabinowitz J ... **Davidson M** ISCTM group. Consistency checks to improve measurement with PANSS Schiz Research 2017
32. Reichenberg A, Cederlöf , McMillan A, Trzaskowski M, Kapara O, Fruchter F, Karen G, **Davidson M** , Weiser M, Plomin R, Lichtenstein L. Discontinuity in the genetic and environmental causes of the intellectual disability spectrum. PNAS 2016
33. Costi S Collings K, **Davidson M**, Iosifescu D Using placebo response to pain as predictor of placebo response in mood disorders Current Behavioural Neuroscience Reports 2016
34. Levi L Werbeloff N Yoffe R Large M **Davidson M** Weiser M Has deinstitutionalization affected inpatient suicide? Schizophrenia Research 2016; 173, 75-78
35. Weiser M, Fenchel D, Werbeloff N, Goldberg S, Fruchter E, Reichenberg A, Burshtein S, Large M, **Davidson M**, Lubin G. The association between premorbid cognitive ability and social functioning and suicide among young men: A historical-prospective study. Eur Neuropsychopharmacol. 2016 (16)32005-3.
36. Weiser M, Goldberg S, Werbeloff N, Fenchel D, Reichenberg A, Shelef L, Large M, **Davidson M**, Fruchter E. Risk of completed suicide in 89,049 young males assessed by a mental health professional Eur Neuropsychopharmacol. 2016 Feb;26(2)341-9.
37. Fruchter F, **Davidson M** ,Weiser M Risk of completed suicide in 89,049 young males assessed by a mental health professional European Neuropsychopharmacology 2016
38. Keefe RS, **Davidson M**,, Stern RG. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bull. 2016 Jan;42(1):19-33.
39. Velthorst E, Reichenberg A, Kapara O, Goldberg S, Fruchter E, Ginat K , **Davidson M**, Weiser M, Developmental trajectories of impaired community functioning in schizophrenia JAMA Psychiatry in Press 2016
40. **Davidson M**, Weiser M. A nation-wide study on the percentage of schizophrenia and bipolar disorder patients who earn minimum wage or above Schizophrenia Bull 2015
41. Werbeloff N, Dohrenwend BP, van Os J, **Davidson M**, Weiser M. The Association between Negative Symptoms, Psychotic Experiences and Later Schizophrenia: A Population-Based Longitudinal Study. PLoS One. 2015 Mar 6;10(3)

42. Werbeloff N, Dohrenwend BP, Levav I, Haklai Z, Yoffe R, Large M, **Davidson M**, Weiser M. Demographic, Behavioral, and Psychiatric Risk Factors for Suicide Crisis. 2015 Dec 23:1-8
43. Weiser M, Kapara O, Werbeloff N, Goldberg S, Fenchel D, Reichenberg A, Yoffe R, Ginat K, Fruchter E, **Davidson M**. A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ Schizophr Res. 2015 Dec;169(1-3):159-64.
44. Knowles EE, Weiser M, David AS, Glahn DC, **Davidson M**, Reichenberg A. The Puzzle of Processing Speed, Memory, and Executive Function Impairments in Schizophrenia: Fitting the Pieces Together. Biol Psychiatry. 2015 Feb 24. S0006-3223(15)
45. Fleisman A, Werbeloff N, Yoffe R, **Davidson M**, Weiser M. Schizophrenia and violent crime: a population-based study M Psychol Med. 2014.
46. Matei VP, Mihailescu AI, **Davidson M**. Is non-pharmacological treatment an option for certain schizophrenia patients? Psychiatr Danub. 2014 Dec;26(4):308-13
47. Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci Schizophrenia Nature 2014 421-427; vol. 511
48. Wobrock T..... **Davidson M**, Kahn R Fleischhacker W Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study Schizophrenia Research 2013
49. Goldberg S, Werbeloff N, Fruchter E, Portuguese S, **Davidson M**, Weiser M. IQ and obesity in adolescence: a population-based, cross-sectional study. Pediatr Obes. 2013
50. Fruchter E, Kapara O, Reichenberg A, Yoffe R, Fono-Yativ O, Kreiss Y, Davidson M, Weiser M. Longitudinal association between epilepsy and schizophrenia: A population-based study. Epilepsy Behav. 2013 Nov 19.
51. Ravona-Springer R, **Davidson M**. Considerations in psychotropic treatments in dementia - can polypharmacy be avoided? Int J Neuropsychopharmacol. 2013
52. Knowles EE, Weiser M, David AS, Dickinson D, Glahn D, Gold J, **Davidson M**, Reichenberg A. Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012
53. Czerniak E, **Davidson M**. Placebo, a historical perspective. Eur Neuropsychopharmacol. 2012 Nov;22(11):770-4.
54. Dollfus S, Alary M, Razafimandimby A, Prelipceanu D, Rybakowski JK, **Davidson M**, Galderisi S, Libiger J, Hranov LG, Hummer M, Boter H, Peuskens J, Kahn RS, Fleischhacker WW; EUFEST Grou Familial sinistrality and handedness in patients with first episode schizophrenia: the EUFEST study. Laterality.2012;17(2):217-24.
55. Weiser M, Heresco U, **Davidson M**, Javitt DC, A multicentre, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. 2012;73:728-34. J Clin Psychiatry
56. Genfen Y, Keefe R, Rabinowitz J, Anand R, **Davidson M** BL1020 a GABA enhanced antipsychotics results of a 6 weeks double blind trial Journal of Clinical Psychiatry 73; 9 2012

57. Sullivan S., Magnusson C. , Reichenberg A. , Boman M. , Dalman C. , **Davidson M** , Lichtenstein P Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism Arch Gen Psych 2012
58. Werbeloff N, Drukker M, Dohrenwend BP, Levav I, Yoffe R, van Os J, **Davidson M**, Weiser M Self reported attenuated psychotic symptoms as runner of severe mental disorders later in life. Arch Gen Psychiatry. 69(5):467-475 2012
59. Patrick F. Sullivan, PF Magnusson C, Reichenberg R, Boman M, Dalman C, **Davidson M**, Fruchter E, Hultman CH, Lundberg M, Långström N, Weiser M, Svensson A, Lichtenstein P Fammily hisotry of schizophrnai and bipolar disorder as a risk factor for autism Arch Gen Psychiatry 2012
60. Geffen Y, Keefe R, Rabinowitz Y, Anand R, **Davidson M** BL-1020 a new GABA-enhanced antipsychotic: Results of Six-Week, Randomized, Double-Blind, Controlled, Efficacy and Safety Study Journal of Clinical Psychiatry 2012
61. Goldberg S, Fruchter E, **Davidson M**, Reichenberg A, Yoffe R, Weiser M The Relationship Between Risk of Hospitalization for Schizophrenia, SES, and Cognitive Functioning 2012 Schiz Bull 2011 Jul;37(4):664-70
62. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.Schizophr Res. 2013 Jun;147(1):132-9.
63. Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. EUFEST Study Group. J Clin Psychopharmacol. 2013 Apr;33(2):258-61.
64. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. Task force on Treatment Guidelines for Schizophrenia. World J Biol Psychiatry. 2013 Feb;14(1):2-44.
65. Ravona R and **Davidson M**: Considerations in psychotropic treatments in dementia, can polypharmacy be avoided? The International Journal of Neuropsychopharmacology 2012
66. Weiser M, Werbeloff N, Dohrenwend BP, Levav I, Yoffe R, **Davidson M**. Do psychiatric registries include all persons with schizophrenia in the general population : A population based longitudinal study Schizophr Res. 2012 Mar;135(1-3):187-91
67. Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C, Bradfield JP, Zhang H, Sleiman PM, Flory JH, Imielinski M, Frackelton EC, Chiavacci R, Thomas KA, Garris M, Otieno FG, **Davidson M**, Weiser M, Reichenberg A, Davis KL, Friedman JI, Cappola TP, Margulies KB, Rader DJ, Grant SF, Buxbaum JD, Gur RE, Hakonarson H.Strong Synaptic Transmission Impact by Copy Number Variations in Schizophrenia. Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10584-7
68. Dollfus S **Davidson M**,..... W.W. Fleischhacker Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study Laterality 2011 In press

69. Weiser M, Werbeloff N, Levine A, Livni G, Schreiber S, Halperin D, Yoffe R, **Davidson M**. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. *Schizophr Res*. 2010 Dec;124(1-3):231-5.
70. **Davidson M**, Galderisi S, Weiser M, Werbeloff N, Fleischhacker W, Keefe R, Boter H, Prelipceanu D Kahn R Cognitive effects of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: A randomized open label clinical trial (EUFEST) 166(6):675-82. *American Journal of Psychiatry* 2009
71. Boter H, Peuskens J, Libiger J, Fleischhacker W, **Davidson M** and Kahn R for the EUFEST study group Effectiveness of antipsychotics in first-episode schizophrenia on response and remission: an open randomized clinical trial (EUFEST) In Press *Schizophrenia Research* 2009
72. Goodwin G, Fleischhacker W, Arango C, Baumann P, **Davidson M**, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J. Advantages and disadvantages of combination treatment with antipsychotics *European Journal of Neuropsychopharmacology* 19, 520-532 2009
73. Kahn RS, Fleischhacker W.W, Boter H, **Davidson M**, Vergouwe I, Keet P, Gheorghe M, Rybakowski J, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor L, Hranov L, Gaebel W, Peuskens J, Riecher-Rössler A, and Grobbee D for the EUEST study group Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: A European Randomized Clinical Trial *Lancet* 2008 29;371(9618):1085-97.
74. Caspi A, Vishne T, Reichenberg A, Weiser M, Dishon A, Lubin G, Shmushkevitz M, Mandel Y, **Davidson M** . Refractive errors and schizophrenia *Schizophrenia Research* Nov 17 2008
75. Kemp A, Schooler N, Kalali A, Alphs A, Anand R, **Davidson M**, Garibaldi G, Leon A, Potkin What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? *S Schizophrenia Bulletin* 1-6, 2008
76. Boter H, Derks E, Fleischhacker W **Davidson M**, René S Kahn, for the EUFEST Study Group Generalizability of the results of efficacy trials in first-episode schizophrenia: Comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST) *J Clin Psychiatry*. 2010 Jan;71(1):58-65v
77. Weiser M **Davidson M** Increased number of offspring in first degree relatives of psychotic individuals: a partial explanation for the persistence of psychotic illnesses". *ACTA Psychiatrica*
78. Weiser M, Reichenberg A, Werbeloff N, Kleinhaus K, Lubin G, Shmushkevitch M, Caspi A, Malaspina D, **Davidson M**. Advanced Parental Age at Birth Is Associated With Poorer Social Functioning in Adolescent Males: Shedding

Light on a Core Symptom of Schizophrenia and Autism. Schizophr Bull vol 34 pp1042-1046 2008

79. Weiser M and **Davidson M** Using Clinical Data Bases to Study Schizophrenia. Schizophr Bull. Bull vol 34 pp1033-1036 2008
80. Beeri M, **Davidson M**, Silverman J Schmeider J. Ravona R Noy S Goldburt U. Religious education and midlife observance are associated with dementia three decades later in Israeli men Journal of Clinical Epidemiology (2008) 1-8
81. Weiser M, Reichenberg M, Kravitz E, Lubin G, Shmushkevich M, Glahn D, Gross R, Rabinowitz J, Noy S, **Davidson M** Subtle cognitive dysfunction in non-affected siblings of individuals affected by non-psychotic disorders Biological Psychiatry 2008 63-6 602-608
82. Brill N, Reichenberg A, Rabinowitz J, Harary E, Lubin G **Davidson M**, Weiser M Accuracy of self-reported premorbid functioning in schizophrenia. Schizophrenia Research 2007, 94: 45-49
83. Weiser M, Reichenberg A, Werbeloff N, Kravitz E, Lubin G, Shmushkevitch M R Yoffe R, Addington J, **Davidson M** Self-report of family functioning and risk for psychotic disorders in male adolescents with behavioural disturbances ACTA Psych. Scand. 2008 Mar;117(3):225-31.
84. Weiser M, Werbeloff N, Vishna T, Yoffe R, Lubin G, Shmushkevitch M, **Davidson M**. Elaboration on immigration and risk for schizophrenia Psychological Medicine In Press 2007
85. Caspi A Reichenberg A Weiser M Rabinowitz J, Shmushkevich M Lubin G Nahon D Vishne T **Davidson M** Premorbid behavioural and intellectual functioning in schizophrenia 3 patients with poor response to treatment with antipsychotic drugs In Press Schizophrenias Research
86. Weiser M, Reichenberg A Rabinowitz J Nahon D Kravitz E Lubin G. Knobler H **Davidson M** Noy S. Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with co-morbid and future psychopathology In Press Journal of Nervous and Mental Disorders 2007
87. Weiser M van Os J Reichenberg A Rabinowitz J Nahon D Kravitz E Lubin G Shmushkevitch M Knobler H Noy S **Davidson M** Social and cognitive functioning, urbanicity and risk for schizophrenia British Journal of Psychiatry Vol 190; 320-324, 2007
88. Goldburt U, Schnaider-Beeri M, **Davidson M**. Socio-economic status in relationship to death from vascular disease and late life dementia. J Neurol Sci. 2007 March

89. **Davidson M**, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdeken M. Efficacy, safety and early response of paliperidone extended-release tablets Results of a 6-week, randomized, placebo-controlled study. In Press Schizophrenia Research 2007
90. **Davidson M** Paliperidone extended release. CNS Drugs 21 (5) 426-426 2007
91. Reichenberg A, Gross R, Weiser M, Bresnahan M, Silverman S, Harlap S, Rabinowitz J, Shulman C, Malaspina D, Lubin, G, Knobler H, **Davidson M**, Susser, E. Advancing Paternal Age and Autism Arch Gen Psychiatry 2006 Sep;63(9):1026-32.
92. Reichenberg A, Caspi A, Weiser M Knobler H **Davidson M** Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb;28(2):193-207.
93. Potkin S, Gharabawi G, Greenspan A, Mahmoud R, Kosik-Gonzales C, **Davidson M**, Burtea V, Trivedi K. A double blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia in patients with schizophrenia experiencing an acute exacerbation Schizophrenia Research 2006 85 254-265
94. Rabinowitz J, Eerdeken, M, **Davidson M** Premorbid functioning and treatment response in recent onset schizophrenia" British Journal of Psychiatry (2 0 0 6) 1 8 9, 31-38
95. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, Knobler HY, Lubin G, Nahon D, Harvey PD, **Davidson M**. Premorbid Intra-Individual-Variability in Intellectual Performance and Risk for Schizophrenia: A Population-Based Study. Schizophrenia Research 2006; vol. 88 No 1-3, pp 49-59
96. Reichenberg A, Weiser M, Rapp M, Rabinowitz J, Caspi A, Schmeidler J, Knobler H, Lubin G, Nahon N Harvey P, and **Davidson M**. Elaboration on Premorbid Intellectual Performance in Schizophrenia: Premorbid Intellectual Decline and Risk for Schizophrenia Arch Gen Psych 2005;62 1297-1304
97. Harvey P, Rabinowitz J, Eerdeken M, **Davidson M** Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a large long-term trial American Journal of Psychiatry 2005;162:1888-95.
98. Weiser M, van Os J, **Davidson M** Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes? British Journal of Psychiatry 2005 187: 203-205
99. Malaspina D, Reichenberg A, Fennig S, **Davidson M**, Harlap, S, Rabinowitz J, Susser E, Knobler H. Paternal Age and Intelligence: Implications for Age Related Genomic Changes in Male Germ Cells Psychiatric Genetics Jun;15(2):117-25.

100. Rabinowitz J, **Davidson M**, De Deyn P, Katz I, Brodaty H, Cohen-Mansfield J . Factor Analysis of the Cohen-Mansfield Agitation Inventory in Three Large Samples of Nursing Home Patients with Dementia and Behavioral Disturbance American Journal of Geriatric Psychiatry 2005 Nov; 13(11):991-8.
101. Weiser M, **Davidson M**, Noy S. Comments on risk for schizophrenia. Schizophr Res June 16 2005
102. Schooler N., Rabinowitz J., **Davidson M**, Emsley R,Harvey P, Kopala L, McGorry P., Van Hove I, Eerdeken, M., Swyzen W, De Smedt G, and Early Psychosis Global Working Group* Risperidone and Haloperidol in First Episode Psychosis: a long-term randomized trial American Journal of Psychiatry 162; 1-7 2005
103. Beeri M, **Davidson M.**, Silverman J, Noy S., Schmeidler J Goldbourt U. The Relationship Between Body Height and Dementia In Press American Journal of Geriatric Psychiatry 2005;13:116-23.
104. **Davidson M**, Caspi A, Noy S The treatment of schizophrenia; from premorbid manifestation to first episode of psychosis Dialogues in Neuroscience vol 7. no 1. 2005
105. Rabinowitz J, Haim R, Reichenberg A, Weiser M, Kaplan Z, Davidson M, Hafner H. Association between functioning in adolescence prior to first admission for schizophrenia and affective disorders and patterns of hospitalizations thereafter. Schiz Res. 2005 Mar 1;73(2-3):185-91
106. Weiser M, Reichenberg A, Rabinowitz J., Knobler HY, Lubin G, Yazvitzky R., Nahon D, Gur R **Davidson M**. Cognitive Performance of Male Adolescents is Lower than Controls Across Psychiatric Disorders: A Population-Based Study” Acta Psychiatrica Scandinavica. Dec;110(6):471-5. 2004
107. Rabinowitz J; Katz I, De Deyn P, Brodaty H. Greenspan A, **M. Davidson** .Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. Journal of Clinical Psychiatry J Clin Psychiatry. 2004 Oct;65(10):1329-34.
108. Barak Y, **Davidson M** , Luxenberg J, Aizenberg,D. Psychiatric Services in Nursing Homes in Israel: Should the American Legislation be Adopted Isr J Psychiatry Relat Sci. 2004;41(3):213-7.
109. Caspi A, **Davidson M**, Tamminga C Treatment-refractory schizophrenia Dialogues in Clinical Neuroscience Vol 6 no 1 23. 2004
110. Weiser M, Knobler HY, Nahon D, **Davidson M** Body Mass Index and future schizophrenia Journal of Clinical Psychiatry 65:1546-1549;2004

111. Weiser M, Kanyas K, Malaspina M, Harvey P, Goetz D, O. Karni, A. Yakir, N. Turetsky, S. Fennig, D. Nahon, B. Lerer and **M. Davidson** Sensitivity of ICD-10 Diagnosis of Psychotic Disorders in the Israeli National Hospitalization Registry , *Comprehensive Psychiatry* 46: 38-42; 2005
112. Beeri M, Goldbourt U, . Silverman JM, Noy S, Schmeidler J, Ravona R Sverdlick A, **Davidson M** Diabetes mellitus in midlife and the risk of dementia three decades later *Neurology* 63: 1902-1907 2004
113. Casey D, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, **Davidson M**, JP Lyndenmayer, Charles Hennekens Antipsychotic induced weight gain and Metabolic abnormalities 2004 *Journal of Clinical Psychiatry J Clin Psychiatry.* 2004;65,:4-18;
114. Werner P, Beeri M, Noy S, **Davidson M** "Describing the social environment of elderly persons at the time of death. *J Palliat Med.* 2005 Apr;8(2):440-7.
115. Beeri M, Silverman J, Davis KL Marin D, Grossman H Schmeidler J, Perl D.; **MI Davidson** , Mohs RC and Haroutunian V Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology *J Gerontol A Biol Sci Med Sci.* 2005 Apr;60(4):471-5.
116. Weiser M, Reichnerg A, Rabinowitz J, Knobler H, **Davidson M** Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study. *American Journal of Psychiatry* 2004 161; 1219-1223
117. **Davidson M** and Weiser M Prodromal schizophrenia: the dilemma of prediction and early intervention *CNS Spectrum* Aug;9(8):578. 2004
118. Lasser RA, Bossie CA, Zhu1 Y, Gharabawi1 G, Eerdeken M, **Davidson M** Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder *Int J Geriatr Psychiatry* 19;1-8, 2004
119. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Kaplan Z., Knobler YH, Davidson-Sagi N, **Davidson M.** Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode *Schizophr Res.* 2003 Dec 15; 65(2-3): 87-94.
120. Melamed Y, **Davidson M.** Bleich A . Placebo-controlled trials in schizophrenia *Harefua* 2004 Mar;143(3):236-40, 244
121. Ravona-Springer R, **Davidson M**, Noy S The role of cardiovascular risk factors in Alzheimer's disease. *CNS Spectr.* 2003 Nov;8(11):824-33.
122. Blesa R **Davidson M** Kurz A Reichmane W B Bart van Baelenf Schwalend S Galantamine Provides Sustained Benefits in Patients with 'Advanced

Moderate' Alzheimer's Disease for at Least 12 Months Dementia and Geriatric Cognitive Disorders 2003;15:79–87

123. Rabinowitz J, Bromet E, **Davidson M**. Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice? *Schizophrenia Research* 2003 (61) 149-155
124. Weiser M, Reichenberg A, Rabinowitz' J, Knobler H, Caspi A, Nahon D and **Davidson M** Self-reported drug abuse in male adolescents with behavioural disturbances, and follow-up for future schizophrenia *Biological Psychiatry* 2003Sept 15;54(6) 655-60
125. Rabinowitz J, De Smedt G, Harvey P, **Davidson M**. The Relationship Between Premorbid Functioning and Symptom Severity as Assessed at First Episode of Psychosis. *American Journal of Psychiatry* 2002; 159: 2021-6.
126. Barak Y, **Davidson M** , Luxenberg J, Aizenberg A Psychiatric Services in Nursing Homes in Israel: Should the American Legislation be Adopted? *Israeli Journal of Psychiatry* 2003
127. Rabinowitz J, Kathib A, **M Davidson**. Percived patients threat nad neuroleptic dosage *Journal of Mental nad Nervouse Disorders* 191(2) pp 129-130
128. Beeri M, Silverman J, Werner P, **Davidson M** Validation of the Modified Telephone Interview for Cognitive Status (TICS-m) in Hebrew *International Journal of Geriatric Psychiatry* in 2003 18; 381-386
129. Reichenberg A, Weiser M, Rabinowitz J, Caspi A, Schmeidler J, Mark M, Kaplan Z, and **Davidson M**. Premorbid intellectual and behavioral functioning in schizophrenia, schizoaffective and non-psychotic bipolar disorder patients: A population-based cohort study *American Journal Psychiatry* 2002; 159: 2027-35
130. Werner P and **Davidson M** Emotional reactions of lay persons to someone with Alzheimer's disease. *Int J Geriatr Psychiatry*. 2004 Apr;19(4):391-7.
131. Ravona R, Noy S, **Davidson M** Is the distinction between Alzheimer's and Vascular dementia posible and relevant? *Dialogues in Clinical Neuroscience* 2003
132. Harvey P.D., Powchik P., Mohs R.S., and **Davidson M**. Memory functions in geriatric schizophrenic inpatients: a neuropsychological study. *J. of Neuropsychiatry and Clinical Neurosciences*.
133. Weiser M , Knobler H, Grotto I, **Davidson M** A Hypotetical attempt to define NNT to delay the first hospitalization for Schizophrenia *Preventive strategies in Schizophrnia* *Giovani Fioriti Editor*

134. Adunsky R, **Davidson M** A cross-sectional study of lipids and ApoC levels in Alzheimer's Patients with and without cardiovascular disease *Journal of Gerontology Medical Sciences* 57(11) 757-61; 2002
135. Adunsky R, Cesnin V, Ravona R **Davidson M** Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: a cross-sectional study. *Arch Gerontol Geriatr.* 2004 Jan-Feb;38(1):61-8.
136. Soares-Weiser K, Weiser M, Davidson M. Use of cannabis in adolescence and risk of schizophrenia *Rev Bras Psiquiatr.* 2003 Sep;25(3):131-2.
137. Beeri M , S. Noy, **Davidson M** The cost of Alzheimer's Disease in Israel *Journal of Alzheimer's Disease and Associated Disorders* 16;2: 73-80, 2002
138. Beeri M, Werner P, **Davidson M**, Noy S The cost of BPSD in community dwelling AD patients. *International Journal of Geriatric Psychiatry* 16; 1-6 2002
139. **Davidson M** Can prodromal and premorbid markers associated with psychosis be utilized for early detection and secondary prevention in schizophrenia? *Dialogues in clinical neuroscience* vol 3; 3. 138-140; 2002
140. **Davidson M.** What else can we do to combat stigma. *World Psychiatry* vol 1 (1) 22-23; 2002
141. **Davidson M.** Risk of Cardiovascular Disease and Sudden Death in Schizophrenia. *Journal of Clinical Psychiatry* 63(9) 5-11; 2002
142. Harvey P and **Davidson M** The life-time course of schizophrenia *Psychopharmacology: A Generation of Progress* pp 641-656; 2002
143. Meltzer H, **Davidson M**, Glassman A, Vieweg V. Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment. *Journal of Clinical Psychiatry* 63(9) pp 25-28 2002
144. Werner P, Beeri M, Aaron J, **Davidson M** Family caregiver's willingness to pay for drugs indicated for the treatment of Alzheimer's disease: An economic or psychological model? *Dementia* vol I (1) 59-74 ; 2002
145. **Davidson M** Long-Term Safety of Risperidone *Journal of Clinical Psychiatry* 62;21 26-28 2001
146. Harari T, Furst M ,Kiryati N, Caspi A, **Davidson M.** A computer -based method for the assessment of body image distortions in Anorexia Nervosa patients. *Journal of Transactions on Information Technology in biomedicine* Vol.5, No3; 311-319, 2001
147. Haroutunian, V., Powchik, P., Purohit, D.P., **Davidson M.**, Perl, D.P. and Davis, K.L. Cognitive deficits without a cholinergic cause: Choline acetyltransferase

activity in the parietal cortex of 95 elderly schizophrenics .2001 Neuroscience Letters 2001

148. Rabinowitz J, Bromet E, **Davidson M**. Comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: naturalistic study *Schizophrenia Bulletin* 27(4) 597-600; 2001
149. Rabinowitz, J., & **Davidson, M**. Risperidone versus Haloperidol in Long-term hospitalized Chronic Patients in a Double Blind Randomized Trial. *Schizophrenia Research* pp 89-93 2001
150. Rabinowitz,J., Lichtenberg, P., Kaplan, Z., Mark ,M., Nahon, D.,& Davidson, M. Rehospitalization Rates Chronic Schizophrenic of Risperidone, Olanzapine or Conventional Antipsychotics. *American Journal of Psychiatry* 2001 158 (2) 266-269
151. Weiser M , Reichenberg A , Rabinowitz J, Kaplan Z Mark M, Bodner E PhD, Nahon D, **M Davidson** Association between Non-psychotic Psychiatric Diagnoses and Schizophrenia in Adolescent Males. *Archives of General Psychiatry* 58:959-964 2001
152. Weiser M, Beeri M, Nakash N, Brill N, Bavnik O, Reiss S, Hocherman S, and **Davidson M**. Improvement in cognition associated with novel antipsychotic drug: a direct effect or reduction in EPS ? *Schizophrenia Research* 46;(2-3) 81-91 2001
153. **Davidson M** and Beeri M Methodological Considerations in Assessing the Cost of Alzheimer's Disease November 2000 *Dialogues in Clinical Neuroscience*
154. **Davidson M** and Weiser M . Early diagnosis of schizophrenia – The first step towards secondary prevention *ACTA Psychiatr Scand* 400; 7-10 2000
155. **Davidson M** Weiser M, Reichenberg A, Rabinowitz J , Kaplan Z, Mark M, premorbid functioning in schizophrenia ... In reply *American Journal of Psychiatry* 157(9):1528
156. **Davidson M**, Weiser M, Soares K. Novel Antipsychotics in the Treatment of Psychosis and Agitation Associated with Dementia: A Meta-Analysis of Randomized Controlled Clinical Trials. *International Psychogeriatrics* (2000). Vol. 12. 271-277
157. **Davidson M**. Harvy PD, J.Vervarcke CA Gagiano D Hooge G Bray M Dose Y Barak and M Haushofer . A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis 2000 *International Journal of Geriatric Psychiatry* vol 15, 506-514
158. Rabinowitz J, Reichenberg A, Weiser M, Mark M, Kaplan Z, **Davidson M**. Cognitive and Behavioral Functioning in Schizophrenia before the First

Hospitalization and Shortly after: A cross-sectional analysis of registry data. British Journal of Psychiatry 2000, Vol. 177, pp.26-32

159. Rabinowitz, J., Hornik, T. & **Davidson M.** Rapid Onset of Therapeutic Effect of Risperidone versus Haloperidol in a Double Blind Randomized Trial. Journal of Clinical Psychiatry 2000
160. Reichenberg A, Rabinowitz J, Weiser W, Mark M, Kaplan Z and **Davidson M.** Premorbid functioning in a national population of male twins discordant for psychoses American Journal of Psychiatry 2000 157: 1514-1516
161. Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Mark M, Nahon N, and **Davidson M;** Gender Differences in Premorbid Cognitive Performance in a National Cohort of Schizophrenic Patients. Schizophrenia Research 27;45(3): 185-190; 2000
162. Agam G., Belmaker R.H., Shimon H., Shapiro J., **Davidson M.**, Haroutunian V. Inositol levels in post mortem brain samples of Alzheimer's patients, 1999 Progress Neuro-Psychopharmacology & Biological Psychiatry
163. **Davidson M,** Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatric Psychiatry 2000 Jun 15 (6) 506-14
164. **Davidson M**, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z and Mark M. Cognitive and behavioral antecedents predicting schizophrenia in a population of healthy adolescents 1999; American Journal of Psychiatry 156:1328-1335
165. Gigi A, Beeri M, **Davidson M,** Prohonik I. Validation of a Hebrew Reminding Test Isr. J. Relat. Sci. vol1 11-17 1999
166. Harvey PD, AU, Parrella M, White L, Mohs RC, **Davidson M,** Davis KL. Cognitive decline in late-life schizophrenia: A longitudinal Study of Geriatric Hospitalized Patients Biological Psychiatry 1999; 45(1):32-40
167. Harvey PD, Parrella M, White L, Mohs RC, **Davidson M** Davis KL Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophrenia Research 1999,35;77-84
168. Ivgi, M., Schneider-Beiri, M., Rabinowitz, J. and **Davidson, M.** A naturalistic study comparing the efficacy of a memory enhancement course to a general academic course in healthy elderly International Psychogeriatrics 1999 Vol 11; 3; 281-287
169. Korczyn AD and **Davidson M.** Quality of life in Alzheimer's disease European Neurology European Journal of Neurology 1999 vol. 4; 487-48

170. Amin F., Stroe A., Kahn T, Knott, Kahn R.S., **Davidson M.** Control of Renal Factors in Plasma Homovanillic Acid Measurements *Neuropsychopharmacology* 18;4: 317-320 1998
171. Harvey P.D., Howanitz E., Parella M., White L., **Davidson M.**, Mohs R., Hoblyn J., Davis K. Cognitive, Adaptive, and Symptomatic Features of Schizophrenia in Late Life: A Comparison of Nursing Home, Chronically Hospitalized and Acutely Admitted Patients, *American Journal of Psychiatry* 1998; 155, 1080-1086
172. Healy DJ, Haroutunian V., Powchick P., **Davidson M.**, Davis K., Watson S.J., Meador-Woodruff J.H. AMPA receptor building and sub-unit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. *Neuropsychopharmacology* 1998 vol. 19, 4, 278-285
173. Powchik P., **Davidson M.**, Haroutunian V., Gabriel S.M., Purohit D.P., Perl D.P., Harvey P.D., Davis K.L. Postmortem studies in schizophrenia with a focus on the biological correlates of cognitive dysfunction. *Schizophrenia Bulletin*, 1998, 325-342.
174. Purohit D.P., **Davidson M.**, Perl D.P., Haroutunian V., Powchik P. and Davis K.L. Alzheimer's disease and related neurodegenerative diseases in elderly schizophrenic patients: A postmortem neuropathology study of 100 cases. *Archives of General Psychiatry*, 1998 55(3):205-11
175. Resnik-Wolf Machado J, Haroutunian V, Goldman B, **Davidson M**, Somatic mutation analysis of the APP and presenile 1 and 2 genes in AD brains. *Journal of Neurogenetics* Jan 12(1) 55-65 1998
176. Reznik-Wolf, Treves T, Chapman J, **Davidson M**, Hyslop PH, Goldamn B, Korzyn A and Fredman E Germline mutation analysis of presenile 1 App genes in Jewish-Israeli individuals with familial or early onset AD *Eur Journal of Human Genetics*, 1998, 6(2) 176-180
177. Shimon H., Sobolev Y. **Davidson M.**, Haroutunian V., Belmaker R.H., Agmon G. Inositol levels are decreased in postmortem brains of schizophrenics. *Biological Psychiatry* 1998 ; 44, 428-432
178. Van Kammen, DP, Leonard B, Cancro R, **Davidson M**, and Uriel Halbreich. Schizophrenia and their treatments 71-92. In *Training in Psychopharmacology* Peter Gaszner and Uriel Halbreich 1998
179. Weiser M, Lapidus R, Abramowitz Y and **Davidson M** EEG in Psychiatric Patients 15 (1-2) 8-9 *Harefua* 1998
180. Barak Y, Swartz M, **Davidson M** Dementia in elderly schizophrenic patients: A review *International Review of Psychiatry* 9; 459-463 1997

181. Gabriel S, Haroutunian V., Powchik P. Honer W.G., **Davidson M.**, Davis P., Davis KL. Increased Concentration of Presynaptic Proteins in the Cingulate of Schizophrenics. *Archive of General Psychiatry*, 1997, 54, 559-566.
182. Harvey P.D., **Davidson M.**, Mueser K.T., Parella M., White L., and Powchik P. The social-adaptive functioning evaluation (SAFE): A rating scale for geriatric psychiatric patients, 1997, *Schizophrenia Bulletin* 23(1): 131-145.
183. Harvey P.D., Lombardi J., Leibman M., Parella M., and White L., Powchik P, **Davidson M.**, and Davis K.L. Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across 9 decades. *American Journal of Psychiatry*, 1997;154, 205-210
184. Harvey P.D., Lombardy J., Leibman M., Parella M., White L., Powchik P., Mohs R.C., Davidson M. Verbal fluency deficits in geriatric and non-geriatric chronic schizophrenic patients. *The Journal of Neuropsychiatry and clinical Neuroscience*. 1997 9(4) :584-590.
185. Harvey PD Leff J Trieman N Anderson J **Davidson M** Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London *International Journal of Geriatric Psychiatry* 1997 12(10):10001-
186. Harvey PD Powchik P Parrella M White L **Davidson M** Symptoms Severity and cognitive impairment in chronically hospitalized geriatric patients with affective disorder *British Journal of Psychiatry* 1997 170: 369-74
187. Harvey PD Sukhodolsky D Parella M White L **Davidson M** The Association between adaptive and cognitive deficit in schizophrenic patients *Schizophrenia Research* 1997 27(2-3):211-8
188. Meador-Woodruff J.H., Haroutunian V., Powchik P., **Davidson M.**, and Davis K., Watson S.J. Dopamine receptor transcript expression in striatum, prefrontal and occipital cortex: Focal abnormalities in area 11 in Schizophrenia. *Archives of General Psychiatry*, 54; 1089-1095, 1997.
189. Powchik P., Friedman J., Haroutunian V., Greenberg D., Altsteil L., Purohit D., Perl D., **Davidson M.** Apolipoprotein E4 in Schizophrenia: A study of 116 cases with concomitant neuropathological examination. *Biological Psychiatry*, 1997,42(4), 296-298.
190. Stern G.R., Kahn R.S., **Davidson M.** Review of Plasma HVA Studies. In: *Plasma Homovanillic Acid in Schizophrenia; Implications for Presynaptic Dopamine Dysfunction* Ed. A Friedhoff and F Amin. American Psychiatric Press Washington DC 1997, 27-42.
191. Stern G.R., Schmeidler J., **Davidson M.** Limitations of controlled augmentation trials in schizophrenia. *Biological Psychiatry* 1997, 42, 138-143

192. Weisser M Levy A **Davidson M** New antipsychotic drugs Harefuah 1997 133 (1-2) : 57-50
193. White L, Parella M., McCristal-Simon R.N., Harvey P.D., and Masiar S.J., **Davidson M**. Characteristics of elderly psychiatric patients retained in a state hospital during downsizing: A prospective study with replication. *International Journal of Geriatric Psychiatry*, 12:470-473, 1997
194. Berman I, Merson, Rachov-Pavlov J, Allan E, **Davidson M** Losonczy MF. Risperidone in elderly schizophrenic patients- an open-label trial. *Journal Geriatr Psychiatry* 1996; 4:173-179.
195. **Davidson M.**, Harvey P.D., Welsh K.A., Powchik P., Putnam K.M. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. *American Journal of Psychiatry* 1996, 153:10, 1274-1279.
196. Gabriel S **Davidson M**, Haroutunian, V., Powchik, P., Bierer, L., Dushyant, P.P., Perl, D.P., Davis, K.L. Neuropeptide deficits in schizophrenia versus Alzheimer's disease cerebral cortex. *Biological Psychiatry*, 1996 39 82-91.
197. Golier J. & **Davidson, M**. Patterns of clinical efficacy for anti psychotic drugs. In John Chernianski *Antipsychotic Drugs*, Chapter 11, 1996.
198. Harvey P D, Lombardi J., Leibman M., White L., Parrella M., Powchik P., Mohs M., **Davidson M**. Performance of geriatric chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia. *International Journal of Geriatric Psychiatry*, 1996, 11, 621-627.
199. Harvey P.D. **Davidson M.**, White L, Mohs R, Davis KL. Empirical Evaluation of Factorial Structure of clinical symptoms in schizophrenia: Effects of typical neuroleptic medication on the BPRS. *Biological Psychiatry* 1996.
200. Harvey P.D., Lombard J., Leibman M., White L., Parella M., Powchik P., **Davidson M**. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: A follow up study. *Schizophrenia Research.*, 1996, 22, 223-231.
201. Harvey PD, **Davidson M.**, White L., Keefe R.S., Hirschowitz J., Mohs R.C., Davis K.L. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. *Biological Psychiatry*, 1996, 40(8), 755-760
202. Keefe SE, Freska E., Apter S.H., **Davidson M.**, Macaluso J.M., Hirschowitz J. and Davis K.L. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings, 1996, *American Journal of Psychiatry*, 1996, 153(6), 806-811.

203. Lombardi J., Harvey D.F., White L., Parrella M., Powchik P., **Davidson M.** Age Disorientation in Chronically Hospitalized Mood Disorder Patients, 1996. *Psychiatry Research*, 1996, 60, 87-90.
204. McLaughlin, D.P., Fox, C.A., Meador-Woodruff, J.H., Haroutunian, V., Powchik, P., **Davidson, M.**, Davis, K.L. and Watson, S.J. Expression of mRNAs encoding key molecules of dopaminergic systems in the Neurons of the A9 region in schizophrenia. *Molecular Psychiatry*, (1996)
205. Putnam, K., Harvey, P.D., White, L., Parrella, M., Kincaid, M., Powchik, P., **Davidson. M.** Symptom stability in geriatric chronic schizophrenic inpatients: A one-year follow-up study. *Biological Psychiatry*, 1996, 39, 92-99.
206. Resnik-Wolf H., Trevese A.T., **Davidson M.**, Aharon-Peretz J., St. George Hyslop PH, Chapman J., Korczyn A.D., Goldman B., Friedman E. A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis., *Human Genetics* 1996, 98, 700-702
207. Rothstein Z., Prohovnik I., **Davidson M.**, Schnaider Beerli M. and Noy S. The economic burden of Alzheimer's Disease in Israel. *The Israeli Journal of Medicine*, 1996 32/11 1120-1123
208. Trestman, R.L., Horvath T.B., Kalus, O., Peterson, AA, Coccaro, E.F., Mitropoulou, V., Apter, S., **Davidson, M.**, Siever, L.J. Event-related potentials in schizotypal personality disorder, *Journal of Neuropsychiatry and Clinical Neuroscience*, 1996, 8(1), 33-44.
209. Zemishlany Z. and **Davidson M.** Lack of Effect of Laboratory-Provoked Anxiety on pHVA concentration in Normal Subjects. *Biological Psychiatry* 1996, 40, 247-252.
210. Amin, F., **Davidson, M.**, Kahn, R.S., Schmeidler, J., Stern, R., Knott, P., Apter, S. Assessment of the central Dopaminergic index (CDI) of plasma homovanillic acid in schizophrenic patients. *Schizophrenia Bulletin*, 21 53-66 1995
211. **Davidson, M.**, Harvey, P.D., Powchik, P., Parella, M., White, L., Knobler, H., Losonczy, M.F., Keefe, R.S., Katz, S., Frecska, E. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. *American Journal of Psychiatry*, 1995, 152(2), 197-207.
212. **Davidson, M.**, Keefe, R. Cognitive impairment as a target for pharmacological treatment in schizophrenia. *Schizophrenia Research*, 1995, vol. 17; 123-129.
213. **Davidson, M.**, Powchik, P. Commentary to "Late onset schizophrenia and late paraphrenia." *Schizophrenia Bulletin*, 21(3), 1995
214. Davis, K.L., Yang, R., **Davidson, M.**, Mohs, R.C., Ryan, TM, Schmeidler, J., Knott, P.J., Thal, L.J., Gamzu, E.R., and the Tacrine Collaborative Study Group.

Alzheimer's disease: Tacrine and Tacrine metabolite concentrations in plasma and cognitive change. *Drug Develop. Research*, 34, 55-65, 1995.

215. Harvey PH, Peter Powchik, Richard Mohs **Davidson. M** Memory Function in Geriatric Schizophrenic Patients. *Journal of Neuropsychiatry and Clinical Neuroscience* 1995, 7, 207-221
216. Harvey, P.D., Lombardi, J., Kincaid, M., White, L., Parrella, M., Powchik, P., **Davidson, M.** Cognitive Functioning in Chronically Hospitalized Schizophrenic Patients: Age-Related Changes and Age Disorientation as a Predictor of Impairments. *Schizophrenia Research*, 17, 15-24, and 1995.
217. Harvey, P.D., Powchik, P., Mohs, R., **Davidson, M.** Memory functions in geriatric schizophrenic inpatients. *Journal of Neuropsychiatry and Clinical Neurosciences*, 1995, 7, 207-212.
218. Harvey, P.D., White, L., Parrella, M., Putnam, K., Kincaid, M., Powchik, P., Mohs, R., Davidson, M. The longitudinal stability of cognitive impairment in schizophrenia: Mini-mental state scores at one and two-year follow-ups in geriatric inpatients. *British Journal of Psychiatry*, 1995, 166, 630-633
219. Kahn, R.S., **Davidson, M.**, Davis, K.L. Dopamine and schizophrenia revisited. In: Watson S. (Ed) *Biology of Schizophrenia and Affective Disease*. Compendium to ARMND conference, December 1995.
220. Keefe, R.S.E., Harvey P.D., Blum, CS PrietoD.M. **Davidson M.**, A pen and paper human analogue of a monkey prefrontal activation task: spatial working memory in patients with schizophrenia. *1995 Schizophrenia Research* 17 125-34
221. Kincaid, M.M., Harvey, P.D., Parrella, M., White, L., Putnam, K.M., Knobler, H., Powchik, P., **Davidson, M.**, Mohs, R.C. The validity and utility of the ADAS-L for the measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. *J Neuropsychiatry Clin Neurosci*, 7(1) 76-811995.
222. Sevy, S., **Davidson, M.** The cost of cognitive impairment in schizophrenia. *Schizophrenia Research*, 1995, 17, 1-5
223. Trestman R.L., Keefe R. S., Mitropoulou V., Harvey P.D., deVegvar M. L., Lees-Roitman S., **Davidson M.**, Aronson A., Silverman J., Siever L.J. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. *Psychiatry Research*, 1995, 59(1-2), 127-136
224. Amin, F., Seeman, T.E., Mohs, R.C., **Davidson, M.** Plasma Homovanillic acid and performance on motor and cognitive tasks in community-dwelling elderly: MacArthur studies of successful aging. *Neuropsychopharmacology*, 10 (1), 29-35, 1994.

225. Gabriel, S.M., Bierer, L., **Davidson, M.**, Purohit, D.P., Perl, D., Haroutunian, V. Galanin- like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. *Journal of Neurochemistry*, 62, 1516-1523, 1994.
226. Haroutunian, V., **Davidson, M.**, Kanof, P.D., Perl, D.P., Powchik, P., Losonczy, M., McCrystal, J., Purohit, D.P., Bierer, L.M., Davis, K.L. Cortical cholinergic markers in schizophrenia. *Schizophrenia Research*, 12, 137-144, 1994.
227. Kahn, R.S., Harvey, P.D., **Davidson, M.**, Keefe, R.S.E., Apter, S., Neale, J, Mohs, R.C., Davis, K.L Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive performance. *Schizophrenia Research*, 11(3), 217-224,1994.
228. Kahn, R.S., Trestman, R., Lawlor, B., Siever, L., **Davidson, M.** Effects of ipsapirone in healthy subjects: A dose-response study. *Psychopharmacology*, 114 (1), 155-160, 1994.
229. Serper M.R., **Davidson, M.**, Harvey, PD. Attentional predictors of clinical response to neuroleptic treatment. *Schizophrenia Research*, 13(1), 65-71, 1994.
230. Stern R., Mohs, R., **Davidson, M.**, Schmeidler, J., Silverman, J., Kramer-Ginsberg, E., Searcey, T., Bierer, L., Davis, K. A longitudinal study of Alzheimer's Disease: Measurement, rate and predictors of cognitive deterioration. *American Journal of Psychiatry*, 151 (3), p.390-396, 1994.
231. Stern, R.G., Kahn, R.S., J., **Davidson, M.**, Nora, R.M., Davis, K.L. Early response to clozapine in schizophrenia *American Journal of Psychiatry*, 151 (12) 1817-1818, 1994.
232. Stern, R.G., Mohs, R.C., **Davidson, M.**, Schmeidler, J, Silverman, J., Kramer-Ginsberg, E., Searcey, T., Bierer, L., Davis, K.L. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. *American Journal of Psychiatry*, 151, 390- 396, 1994.
233. White, L., Harvey, P.D., Parrella, M., Sevy, S., Knobler, H., Powchik, P., **Davidson, M.**, Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Symptom structure in geriatric and non-geriatric samples. *New Trends Exper Clin Psychiatry*, 10, 75-83, 1994.
234. Bierer, L.M., Aisen, P.S., **Davidson, M.**, Ryan, TM, Stern, R.G., Schmeidler, J., Davis, K.L. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer's disease. *Alzheimer's Disease and Associated Disorders*. 7(2), 98-104, 1993.
235. **Davidson, M.**, Kahn, R.S., Stern, R.G., Hirschowitz, J., Apter, S., Knott, P., Davis, K.L. Treatment with clozapine and its effect on plasma homovanillic acid and

- norepinephrine concentrations in schizophrenia. *Psychiatry Research*, 46(2), 151-163, 1993.
236. Harvey, P.D., Mohs R.C., **Davidson, M.** Leukotomy and aging in chronic schizophrenia: a follow-up study 40 years after psychosurgery. *Schizophrenia Bulletin*, 19(4), 723-732, 1993.
 237. Kahn R.S. and **Davidson M.** Serotonin receptor responsivity in schizophrenia. *International Clinical Psychopharmacology*. 2, 47-51, 1993.
 238. Kahn, R.S., **Davidson, M.** Serotonin receptor responsivity in schizophrenia. *International Clinical Psychopharmacology*, Suppl. 2 (8), 47-51, 1993.
 239. Kahn, R.S., **Davidson, M.** On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia. *Neuropharmacology*, 8, 93-95, 1993.
 240. Kahn, R.S., **Davidson, M.** Serotonin, dopamine and their interactions in schizophrenia: An editorial. *Psychopharmacology*, Suppl 112 (1), 1-4, 1993.
 241. Kahn, R.S., **Davidson, M.**, Knott, P., Stern, R.G., Apter, S.A., Davis, K.L. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia: Serotonin-dopamine interactions as a target for treatment, *Archives of General Psychiatry*, 50 (8), 599-605, 1993.
 242. Kahn, R.S., **Davidson, M.**, Siever, L., Gabriel, S., Apter, S., Davis, K.L. Serotonin function and treatment response to clozapine in schizophrenia. *American Journal of Psychiatry*, 150 (9), 1337-1342, 1993.
 243. Kahn, R.S., **Davidson, M.**, Siever, L., Greenwald, C., Moore, C., Davis, K.L. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: Implications for clozapine's mechanism of action. *Psychopharmacology*, 112(1), 90-94, 1993.
 244. Powchik, P., **Davidson, M.**, Nemeroff, CB, Haroutunian, V., Purohit, D., Losonczy, M.F., Bissette, G., Perl, D., Ghanbari, H., Miller, B., Davis, K.L. Alzheimer's disease related protein in geriatric schizophrenic patients with cognitive impairment. *American Journal of Psychiatry*, 150, 1726-1727, 1993.
 245. Purohit, D.P., **Davidson, M.**, Perl, D.P., Powchik, P., Haroutunian, V.H., Bierer, L.M., McCrystal, J., Losonczy, M., Davis, K.L. Severe cognitive impairments in elderly schizophrenic patients: A clinicopathological study. *Biological Psychiatry*, 33(4), 255-260, 1993.
 246. Schmauss, C., Haroutunian, V., Davis, K.L., **Davidson, M.** Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. *Proceedings of the National Academy of Sciences*, 90, 8942-8946, 1993.

247. Siever, L.J., Amin, F., Coccaro, E.F., Trestman, R., Silverman, J., Horvath, T.B., Mahon, T.R., Knott, P., Altstiel, L., **Davidson, M.**, Davis, K.L. Cerebrospinal fluid homovanillic acid in schizotypal personality disorder. *American Journal of Psychiatry*, 150 (1), 149-151, 1993.
248. Silverman, J.M., Siever, L.J., Coccaro, E.F., Klar, H., **Davidson, M.**, Pinkham, L., Apter, S.H., Davis, K.L. Schizophrenia-related and affective personality disorder traits in relatives of schizophrenic and personality disorder probands. *American Journal of Psychiatry*, 150 (3), 435-442, 1993.
249. Stern, R.G., Kahn, R.S., **Davidson, M.** Predictors of response to neuroleptic treatment in schizophrenia. *Psychiatric Clinics of North America*, 16(2), 313-338, 1993.
250. Amin, F., **Davidson, M.**, Davis, and K.L. Homovanillic acid measurement in clinical research: A review of methodology. *Schizophrenia Bulletin*, 18(1), 123-148, 1992.
251. **Davidson, M.**, Kahn, R.S., Davis, K.L. Letter to the Editor. Reply to: Neuroleptic Treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited (Volovka, et al) *Archives of General Psychiatry*, 49, 1000, 1992.
252. Davis, K.L., **Davidson, M.**, Kahn, R.S., Ko, G. Letter to the Editor. *American Journal of Psychiatry* 149, 1285, 1992
253. Harvey, P.D., **Davidson, M.**, Powchik, P., Parella, M., White, L., Mohs, R.C. Assessment of dementia in elderly schizophrenics with structured rating scales. *Schizophrenia Research*, 7, 85-90, 1992.
254. Kahn, R.S., **Davidson M.**, Hirschowitz, J., Stern, R.G., Moore, C. & Davis, K.L. Nocturnal growth hormone secretion in schizophrenia and healthy subjects. *Psychiatry Research*, 41, 155-161, 1992.
255. Kahn, R.S., Knott, P., Gabriel, S., DuMont, K., Mastroianni, L., **Davidson, M.** Effect of m-chlorophenylpiperazine on Plasma Homovanillic Acid Concentrations in Healthy Subjects. *Biological Psychiatry*, 32, 1055-1061, 1992.
256. Kahn, R.S., Siever, L., Gabriel, S., Amin, F., Stern, R.G., DuMont, K., Apter S., **Davidson, M.** Serotonin function in schizophrenia: Effects of m-chlorophenylpiperazine in schizophrenic patients and healthy subjects. *Psychiatry Research*, 43, 1-12, and 1992.
257. Keefe, R.S.E., Harvey, P.D., Lenzenweger, M.F., **Davidson, M.**, Apter, S.H., Schmeidler, J., Mohs, R.C., and Davis, K.L. Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia: Negative Symptoms. *Psychiatry Research*, 44, 153-165, 1992.

258. Lawlor, BA, Tsuboyama, G., Ryan, T., Mohs, R.C., Davis, B.M., **Davidson, M.**, Gabriel, S., Davis, K.L. Agitation and postdexamethasone cortisol in Alzheimer's disease. *American Journal of Psychiatry*, 149(4), 546-548, 1992.
259. Stern, R.G., Mohs, R.C., Bierer, L.M., Silverman, J.M., Schmeidler, J., **Davidson, M.**, Davis, K.L. Deterioration on the Blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes. *Psychiatry Research* 42, 101-110, 1992.
260. Tsuboyama, G.K., Gabriel, S. Davis, B.M., **Davidson, M.**, Lawlor, BA, Ware, K., Davis, K.L., Mohs, R.C. Neuroendocrine dysfunction in Alzheimer's disease: Results following TRH stimulation. *Biological Psychiatry*, 32(2), 195-198, 1992
261. **Davidson, M.**, Kahn, R.S., Knott, P., Kaminsky, R., Cooper, M., DuMount, K., Apter, S., Davis, K.L. Effect of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. *Archives of General Psychiatry*, 48(10), 910-913, 1991.
262. **Davidson, M.**, Kahn, R.S., Warne, P., Powchik, P., Kaminsky, R., Apter, S., Jaff, S., Davis, K.L. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. *Archives of General Psychiatry*, 48, 73-76, and 1991.
263. **Davidson, M.**, Stern, R., Bierer, L.M., Horvath, T.B., Zemishlani, Z., Markofsky, R., Mohs, R.C. Cholinergic strategies in the treatment of Alzheimer's disease. *ACTA Psychiatrica Scandinavica*, 366; 47-51, 1991.
264. **Davidson, M.**, Stern, R.G. The treatment of cognitive impairment in Alzheimer's disease: Beyond the cholinergic approach. In: Davidson, M. (Ed.) *The Psychiatric Clinics of North America: Alzheimer's disease*. W. B. Saunders Co., 14(2), 461-482, 1991. Davidson, M. Neuropeptides. In: Davis, K.L., Klar, H., and Coyle, JT (Eds). *Brain, Behavior and Psychiatry*. W.B. Saunders, Co., Pennsylvania, 92-98, 1991.
265. Davis, K.L., Kahn, R.S., Ko, G. **Davidson, M.** Dopamine in Schizophrenia: A review and reconceptualization. *American Journal of Psychiatry*, 148(11), 1474-1486, 1991.
266. Earle-Boyer, E.A., Serper, M.R., **Davidson, M.**, Harvey, and P.D. Continuous performance tests in schizophrenic patients: Stimulus and medication effects. *Psychiatry Research*, 37(1), 47-56, 1991.
267. Harvey P.D., **Davidson, M.**, Powchik, P., Schmeidler, J., McQueeney, R., Kaminsky, R., Davis, K.L. Time course and clinical predictors of treatment response in schizophrenia. *Schizophrenia Research*, 5(2), 161-166, 1991.
268. Harvey, P.D., Putnam, K.M., **Davidson, M.**, Kahn, R.S., Powchik, P., McQueeney, R., Keefe, R.S.E., Davis, K.L. Brief neuroleptic discontinuation and clinical

- symptoms in Kraepelinian and Non-Kraepelinian chronic schizophrenic patients. *Psychiatric Research*, 38(3), 285-292, 1991.
269. Kahn, R.S., **Davidson, M.**, Kanof, P., McQueeney, R.T., Singh, R.R., Winnick, R., Davis, K.L. Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: A study of prostaglandin-dopamine interactions. *Psychopharmacology*, 103, 95-98, 1991.
270. Kanof, P.D., Mohs, R.C., Gross, J., **Davidson, M.**, Bierer, L.M., Davis, K.L. Platelet phospholipid synthesis in Alzheimer's disease. *Neurobiology of Aging*, 12, 65-69, 1991.
271. Keefe, R.S.E., Lobel, D.S., Mohs, R.C., Silverman, J.M., Losonczy, M.F., **Davidson, M.**, Harvey, P.D., Davis, K.L. Diagnostic issues in chronic schizophrenia: Kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. *Schizophrenia Research*, 4, 71-79, 1991.
272. Moscowitz, J., **Davidson, M.**, Harvey, P.D. The effects of concurrent distraction on communication in schizophrenic patients: Medication status correlations. *Schizophrenia Research*, 5(2), 153-159, 1991.
273. Siever, L.J., Amin, F., Coccaro, E.F., Bernstein, D., Kavoussi, R.J., Klaus, O., Horvath, T.B., Warne, P., **Davidson M.**, Davis, K.L. Plasma homovanillic acid in schizo-typical personality disorder. *American Journal of Psychiatry*, 148(9), 1246-1248, 1991.
274. Silverman, J.M., Pinkham, L., Horvath, T.B., Coccaro, E.F., Klar, H., Shear, S., Apter, S., **Davidson, M.**, Mohs, R.C., Siever, L.J. Affective and impulsive personality disorder traits in the relatives of borderline personality disorder patients. *American Journal of Psychiatry*, 148, 1378-1385, 1991.
275. Stern, R.G., Duffelmeyer, M.E., Zemishlany, Z., Davidson, M. The use of benzodiazepines in the management of behavioral symptoms in demented patients. In: **Davidson, M.** (Ed.) *The Psychiatric Clinics of North America: Alzheimer's disease*. B. Saunders Co., 14(2), 375-384, 1991.
276. Zemishlany, Z., **Davidson, M.**, Jaff, S., McQueeney, R. Acute administration of alprazolam has no effect on plasma homovanillic concentrations in normal subjects. *Schizophrenia Research*, 5(1), 81-83, 1991.
277. **Davidson, M.**, Jaff, S., Davis, K.L. Clinical investigations of plasma homovanillic acid concentrations. *Plasticity and Morphology of the Central Nervous System*. Academic Publishers, Lancaster 203-2, 1990.
278. Davidson, M., Harvey, P.D., Powchik, P., Bergman, R.L., Kaminsky, R., Losonczy, M.F., Davis, K.L. Effects of the D1 agonist SKF - 38393 combined with haloperidol in schizophrenic patients. *Archives of General Psychiatry*, 47(2), 190-191, and 1990.

279. Kahn, R.S., Amin, F., Powchik, P., Goldstein, M., Apter, S., Kerman, B., Jaff, S., **Davidson, M.** Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 14, 879-884, and 1990.
280. Kaminsky, R., Moriarty, TM, Bodine, J., Wolfe, D.E., **Davidson, M.** Effect of famotidine on deficit symptoms of schizophrenia. *Lancet*, 335, 1351-1352, 1990.
281. Kaminsky, R., Powchik, P., Warne, P.A., Goldstein, M., McQueeney, R.T., **Davidson, M.** Measurement of plasma homovanillic acid concentrations in schizophrenic patients. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 14(3), 271-287, and 1990.
282. Keefe, R.S.E., Mohs, R.C., Silverman, J.M., Losonczy, M.F., **Davidson, M.**, Horvath, T.B., Davis, K.L. Characteristics of Kraepelinian schizophrenia In: Schulz, S.C. and Angrist, B. (eds.), *Neuroleptic Augmentation for Treatment Refractory Schizophrenic Patients*, American Psychiatric Press, 3-21, 1990.
283. Siever, L.J., Coccaro, E.F., **Davidson, M.**, Howard, L., Harter, L., & Davis, K.L. Vulnerability and plasticity of monoamine neurotransmitter systems in affective and personality disorders. In *Plasticity and Morphology of the Central Nervous System*. Academic Publishers, Lancaster, UK, 231-249, 1990.
284. Siever, L.J., Keefe, R.S.E., Bernstein, D.P., Coccaro, E.F., Klar, H.M., Zemishlany, Z., Peterson, A.E., **Davidson, M.**, Mahon, T., Horvath, T.B., Mohs, R.C. Eye tracking impairment in clinically identified patients with schizotypal personality disorder. *American Journal of Psychiatry*, 147(6), 740-745, 1990.
285. Zemishlany, Z., McQueeney, R., Gabriel, S.M., **Davidson, M.** Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. *Neuropsychobiology*, 23, 124-128, 1990.
286. **Davidson, M.**, Bierer, L.M., Kaminsky, R., Ryan, TM, Davis, K.L. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer's type. *Alzheimer's Disease and Associated Disorders*, 3(4), 224-227, 1989.
287. Harvey, PD, **Davidson, M.**, Davis, K.L., Bastiaens, and L. Change in subtype presentation in schizophrenics: Associations with medication and overall BPRS scores. *Comprehensive Psychiatry*, 30(1), 114-116, 1989.
288. Kanof, PD, Coccaro, E.F., Johns, C.A., **Davidson, M.**, Siever, L.J., Davis, K.L. Cyclic-AMP production of polymorphonuclear leukocytes in psychiatric disorders., 25, 413-420, 1989.
289. Keefe, R.S.E., Mohs, R.C., Losonczy, M.F., **Davidson, M.**, Silverman, J.M., Horvath, T.B., Davis, K.L. Premorbid socio-sexual functioning and long-term

- outcome in schizophrenia. *American Journal of Psychiatry*, 146(2), 206-211, 1989.
290. **Davidson, M.**, Bastiaens, L., Shah, M., Davis, K.L. Endocrine changes in Alzheimer's disease patients. *Neurologic Clinics*, 6(1), 149-157, 1988.
291. **Davidson, M.**, Davis, B.M., Bastiaens, L., Macaluso, J., Aryan, M., Ryan, T., Davis, K.L. Growth hormone response to edrophonium in patients with Alzheimer's Disease and normal control subjects. *American Journal of Psychiatry*, 145(8), 1007-1009, 1988.
292. **Davidson, M.**, Davis, K.L. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. *Archives of General Psychiatry*, 45(6), 561-563, and 1988.
293. **Davidson, M.**, Freed, L.B., Bastiaens, L., Kaminsky, R., Davis, K.L. Clinical studies of homovanillic acid. In: Belmaker, R.H., Sandler, M., Dahlstrom, A. (eds.), *Progress in Catecholamine Research Part C: Clinical Aspects*, Alan R. Liss, Inc., New York, 137-141, 1988.
294. **Davidson, M.**, Hollander, E., Zemishlany, Z., Cohen, L.J., Mohs, R.C., Davis, K.L. Cholinergic agonists in Alzheimer's disease patients. In: Giacobini, E., and Becker, R. (Eds.) *Current Research in Alzheimer's Therapy*. Taylor and Francis, New York, 333-336, 1988.
295. **Davidson, M.**, Keefe, R.S.E, Mohs, R.C., Siever, L.J., Bergman, R.L., Losonczy, M.F., Horvath, T.B., Davis, K.L. L-dopa challenge and relapse in schizophrenia. Letter to the editor. *American Journal of Psychiatry*, 145(3), 387-388, 1988.
296. **Davidson, M.**, Losonczy, M.F., Mohs, R.C., Davis, B.M., Ryan, TA, Keefe, R.S.E., Davis, K.L. Neuroendocrine and cerebrospinal measurements in schizophrenic patients with tardive dyskinesia. In: Wolf, M.E. *Tardive Dyskinesia: Biological Mechanisms & Clinical Aspects*. APA Press, 39-48, 1988.
297. **Davidson, M.**, Powchik, P., Davis, K.L. Pisa syndrome in a patient with Alzheimer's disease. *Biological Psychiatry*, 23, 209-210, 1988.
298. **Davidson, M.**, Zemishlany, Z., Mohs, R.C., Horvath, T.B., Powchik, P., Blass, J.P., Davis, K.L. 4-Aminopyridine in the treatment of Alzheimer's disease. *Biological Psychiatry*, 21, 485-490, 1988.
299. Davis, K.L., **Davidson, M.**, Yang, R.K., Davis, B.M., Siever, L.J., Mohs, R.C., Ryan TM, Bierer, L., Targum. CSF somatostatin in Alzheimer's disease, depressed patients and control subjects, *Biological Psychiatry*, 24, 710-712, and 1988.
300. Kanof, P., Johns, C.A., **Davidson, M.**, Siever, L.J., Coccaro, E.F., Davis, K.L. Platelet alpha₂-adrenergic receptor function in psychiatric disorders. *Psychiatry Research*, 23, 11-22, and 1988.

301. Keefe, R.S.E., Mohs, R.C., **Davidson, M.**, Losonczy, M.F., Silverman, J.M., Lesser, J.C., Horvath, T.B., Davis, K.L. Kraepelinian schizophrenia: a subgroup of schizophrenia? *Psychopharmacology Bulletin*, 24, 56-61, 1988.
302. Kramer-Ginsburg, E., Mohs, R.C., Aryan, M., Lobel, D., Silverman, J., **Davidson, M.**, Davis, K.L., Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report. *Psychopharmacology Bulletin*, 24(3), 458-462, 1988.
303. Sorokin, J., Giordani, B., Mohs, R.C., **Davidson, M.**, Siever, L.J., Ryan, TA, Davis, K.L. Memory impairment in schizophrenic patients with tardive dyskinesia. *Biological Psychiatry*, 129-135, 1988.
304. Zemishlany, Z., **Davidson, M.** The search for biological markers for schizophrenia. *Harefuah, Journal of the Israel Medical Association*, 114, 344-347, 1988.
305. **Davidson, M.**, Giordani, A., Mohs, R.C., Horvath, T.B., Powchik, P., Davis, B.M., Davis, K.L. Short term haloperidol administration acutely elevates human plasma homovanillic acid concentration. *Archives of General Psychiatry*, 44, 189, and 1987.
306. **Davidson, M.**, Giordani, A., Mohs, R.C., Mykytyn, V.V., Platt, S., Aryan, Z.S., Davis, K.L. Control of exogenous factors affecting plasma HVA. *Psychiatry Research*, 20, 307-312, 1987.
307. **Davidson, M.**, Keefe, R.S.E., Mohs, R.C., Siever, L.J., Losonczy, M.F., Horvath, T.B., Davis, K.L. L-dopa challenge and relapse in schizophrenia. *American Journal of Psychiatry*, 44(7) 934-938, 1987.
308. **Davidson, M.**, Losonczy, M.F., Mohs, R.C., Lesser, J., Powchik, P., Freed, L., Davis, B.M., Mykytyn, V., Davis, K.L. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. *Neuropsychopharmacology*, 1, 17-23, 1987.
309. **Davidson, M.**, Losonczy, M.F., Mohs, R.C., Powchik, P., Freed, LB, Kaminsky, R., Davis, K.L. Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients. *Psychopharmacology Bulletin*, 23(3), 407-410, 1987.
310. **Davidson, M.**, Mohs, R.C., Hollander. Zemishlany, Z., Powchik, P., Ryan, T., Davis, K.L. Lecithin and Piracetam in patients with Alzheimer's disease. *Biological Psychiatry*, 22, 112-116, 1987.
311. Davis, K.L. Hollander, E., **Davidson, M.**, Davis, B.M., Mohs, R.C., Horvath, T.B. Induction of depression with Oxotremorine in patients with AD. *American Journal of Psychiatry*, 144(4), 468-471, 1987

312. Hollander, E., Davidson, M., Mohs, R.C., Horvath, T.B., Davis, B.M., Zemishlany, Z., Davis, K.L. RS86 in the treatment of Alzheimer's disease: cognitive and biological effects. *Biological Psychiatry*, 22(9), 1067-1078, 1987.
313. Hollander, E., Kapell, L.A., Mohs, R.C., **Davidson, M.**, Davis, B.M., Horvath, T.B., Davis, K.L. Oral physostigmine in the treatment of Alzheimer's disease. *Geriatric Medicine Today*, 6(4), 69-76, 1987.
314. Kanof, P., **Davidson, M.**, Johns, C.A., Mohs, R.C., Davis, K.L. Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. *American Journal of Psychiatry*, 144(12), 1556-1560, 1987.
315. Keefe, R.S.E., Mohs, R.C., Losonczy, M.F., **Davidson, M.**, Silverman, J.M., Kendler, K.S., Horvath, T.B., Nora, R., Davis, K.L. Characteristics of very poor outcome schizophrenia. *American Journal of Psychiatry* 144(7), 889-895, 1987.
316. Losonczy, M.F., **Davidson, M.**, Davis, K.L. The dopamine hypothesis of schizophrenia. In: Meltzer, H.Y., ed. *Psychopharmacology: The Third Generation of Progress*, Raven Press, 715-726, 1987.
317. Siever, L.J., Coccaro, E.F., Zemishlany, Z., Silverman, J.M., Klar, H., Losonczy, M.F., **Davidson, M.**, Friedman, R., Mohs, R.C., Davis, K.L. Psychobiology of personality disorders: pharmacological implications. *Psychopharmacology Bulletin*, 3(3), 333-336, 1987.
318. Silverman, J.M., Mohs, R.C., **Davidson, M.**, Losonczy, M.F., Keefe, R.S.E., Breitner, J.C.S., Sorokin, J.E., Davis, K.L. Familial schizophrenia and treatment response. *American Journal Psychiatry*, 144(10), 1271-1276, 1987.
319. Zemishlany, Z., **Davidson, M.**, Davis, K.L. Cholinergic agents in the treatment of Alzheimer's disease. *Harefuah, Journal of the Israel Medical Association*, 1987.
320. **Davidson, M.**, Haroutunian, V., Mohs, R.C., Davis, B.M., Horvath, T.B., Davis, K.L. Human and animal studies with cholinergic agents: how clinically exploitable is the cholinergic deficiency in Alzheimer's disease? In: Fisher, A., Hanin, and I., Lachman C. (Eds). *Plenum Publishing* 29, 531-538, 1986.
321. **Davidson, M.**, Kendler, K.S., Mohs, R.C., Davis, B.M., Ryan, T., Davis, K.L. Effect of Apomorphine Infusion on pHVA in normal subjects. *Journal of Psychiatry Research*, 20, 131-135, 1986.
322. **Davidson, M.**, Losonczy, M.F., Davis, K.L. The biology of schizophrenia. In: Berger, P.A., Brodie, K.H. (eds.), *American Handbook of Psychiatry*. Basic Books, 429-465, 1986.
323. **Davidson, M.**, Mohs, R.C., Hollander, E., Davis, B.M., Ryan, T., Horvath, T.B., Davis, K.L. Physostigmine in patients with Alzheimer's disease. *Psychopharmacology Bulletin*, 22(1), 101-105, 1986.

324. Davis, K.L., Fiori, M., Davis, B.M., Mohs, R.C., Horvath, T.B., **Davidson, M.** Dopaminergic dysregulation in schizophrenia. *Drug Development Research*, 9, 71-83, and 1986.
325. Johns, C.A., Mohs, R.C., Davis, B.M., Greenwald, B.S., Horvath, T.B., Davidson, M., Hollander, E., Davis, K.L. Clinical studies of cholinergic deficit in Alzheimer's disease. *International Conference: The Dynamics of Cholinergic Function*, Monograph, Plenum Press, New York, 1986.
326. Kanof, P., Johns, C.A., **Davidson, M.**, Siever, L.J., Coccaro, E.F., Davis, K.L. Prostaglandin receptor sensitivity in psychiatric disorders. *Archives of General Psychiatry*, 43, 987-993, and 1986.
327. Losonczy, M.F., Song, I.S., Mohs, R.C., Small, NA, **Davidson, M.**, Davis, B.M., Davis, K.L. Correlates of lateral ventricular size in chronic schizophrenia II. Biological measures. *American Journal of Psychiatry*, 143 (9), 1113-1117, 1986.
328. Losonczy, M.F., Song, I.S., Mohs, R.C., Small, NA, **Davidson, M.**, Johns, C.A., Davis, K.L. Correlates of lateral ventricular size in chronic schizophrenia I. Behavioral and treatment response measures. *American Journal of Psychiatry*, 143(8), 976-981, 1986.
329. Siever, L.J., Coccaro, E.F., Klar, H., Zemishlany, Z., **Davidson, M.**, Losonczy, M.F., Silverman, J.M., Mohs, R.C., Davis, K.L. Boundaries of schizophrenia with schizophrenia-related personality disorders: Biologic studies. *Journal of Clinical Neuropsychopharmacology*, 9(4), 274-278, 1986.
330. **Davidson, M.**, Kendler, K.S., Davis, B.M., Horvath, T.B., Mohs, R.C., Davis, K.L. Apomorphine has no effect on plasma homovanilic acid in schizophrenic patients. *Psychiatry Research*, 16, 95-99, 1985.
331. Davis, K.L., **Davidson, M.**, Mohs, R.C., Kendler, K.S., Davis, B.M., Horvath, T.B. Plasma homovanilic acid concentrations and severity of schizophrenia *Science*, 227, 1601-1602, 1985.
332. **Davidson, M.**, Mukherjee S Progression of olfactory references syndrome to Mania. *American Journal of Psychiatry*, 139,1623-1624, 1982.